Immurait-Ll2Mab Biosimilar – Anti-CD22 mAb – Research Grade

Description of Immurait-Ll2Mab Biosimilar - Anti-CD22 mAb - Research Grade

Introduction

Immurait-Ll2Mab Biosimilar is a monoclonal antibody (mAb) that specifically targets CD22, a cell surface protein found on B cells. This biosimilar is a research grade version of the original anti-CD22 mAb, and is used in various scientific studies and experiments. In this article, we will provide a detailed description of the structure, activity, and applications of Immurait-Ll2Mab Biosimilar as an antibody targeting CD22.

Structure of Immurait-Ll2Mab Biosimilar

Immurait-Ll2Mab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to the CD22 protein, while the constant region plays a role in immune effector functions.

The heavy and light chains of Immurait-Ll2Mab Biosimilar are connected by disulfide bonds, creating a Y-shaped structure. The variable regions of the heavy and light chains come together to form the antigen-binding site, which is responsible for the specific binding to CD22. This structure allows Immurait-Ll2Mab Biosimilar to selectively recognize and bind to CD22, making it a highly specific therapeutic agent.

Activity of Immurait-Ll2Mab Biosimilar

The main activity of Immurait-Ll2Mab Biosimilar is its ability to bind to CD22 on the surface of B cells. CD22 is a transmembrane protein that is primarily expressed on B cells and plays a role in regulating B cell activation and survival. By binding to CD22, Immurait-Ll2Mab Biosimilar can modulate B cell function and potentially inhibit the growth and proliferation of B cell malignancies.

In addition to its direct binding to CD22, Immurait-Ll2Mab Biosimilar also has immune effector functions through its constant region. This includes the ability to recruit and activate immune cells, such as natural killer cells and macrophages, to attack and eliminate CD22-expressing cells. This makes Immurait-Ll2Mab Biosimilar not only a therapeutic agent but also a potential immunotherapeutic agent.

Applications of Immurait-Ll2Mab Biosimilar

As a research grade antibody targeting CD22, Immurait-Ll2Mab Biosimilar has various applications in scientific studies and experiments. One of its main applications is in the field of oncology, where CD22 is a therapeutic target for B cell malignancies such as non-Hodgkin’s lymphoma and acute lymphoblastic leukemia.

Immurait-Ll2Mab Biosimilar can also be used in the study of B cell biology and immune responses. By specifically targeting CD22, researchers can investigate the role of this protein in B cell development, activation, and survival. This can provide insights into the pathogenesis of B cell-related diseases and potentially lead to the development of new therapeutic strategies.

Furthermore, Immurait-Ll2Mab Biosimilar can be used in preclinical studies to evaluate its efficacy and safety in various disease models. This can help in the development of new treatments for CD22-positive diseases and provide valuable data for clinical trials.

Conclusion

In summary, Immurait-Ll2Mab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that specifically targets CD22 on B cells. Its structure allows for specific binding to CD22, while its immune effector functions provide potential therapeutic and immunotherapeutic benefits. As a research grade antibody, Immurait-Ll2Mab Biosimilar has various applications in the study of B cell biology and in the development of new treatments for CD22-positive diseases. Its use in scientific research continues to contribute to